Octagam (Human Normal Immunoglobulin)

Human Normal Immunoglobulin supplies pooled IgG antibodies that bind to pathogens, neutralise toxins, and interact with immune‑cell receptors. This restores deficient antibody levels, modulates complement activation and Fc‑receptor signalling, and provides anti‑inflammatory effects that help control autoimmune activity and reduce infection risk.

The dosing regimen for Octagam is individualized by the prescribing clinician based on the patient’s weight, indication, and clinical response. Doses are usually calculated in grams per kilogram of body weight and administered as an intravenous infusion over several hours.

Human normal immunoglobulin is classified as a Category C product; limited data suggest it can be used when the potential benefit outweighs any potential risk to the fetus. It is excreted in small amounts in breast milk, so clinicians weigh maternal benefit against infant exposure before prescribing.

To order Octagam, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling) and any necessary import documentation.

Octagam is a 10 % liquid IVIG formulation comparable to other branded immunoglobulins such as Privigen or Gamunex. Differences may include stabiliser composition, infusion tolerability, and specific manufacturing processes. Clinical efficacy is generally similar, while individual patient tolerance can vary, making product selection a matter of clinician preference and patient response.

Octagam should be stored refrigerated at 2 °C to 8 °C. The product must be kept in its original container, protected from light, and must never be frozen or shaken. Once removed from refrigeration, it should be used within the time frame specified in the product label.

Octagam is given as an intravenous infusion. The infusion rate is started slowly and may be increased as tolerated, typically over 2–4 hours depending on the dose and patient’s reaction. Administration should be performed by trained healthcare professionals in a setting equipped to manage potential infusion reactions.

Serious risks include severe hypersensitivity reactions such as anaphylaxis, acute renal failure, thromboembolic events, hemolytic anemia, aseptic meningitis, and severe thrombocytopenia. Prompt recognition and management of these events are essential, and patients should be monitored closely during and after infusion.

Octagam is contraindicated in patients with a known severe hypersensitivity to immunoglobulin products or any of its excipients. It should also be avoided in individuals with uncontrolled hyperviscosity, active thrombotic disease, or severe renal impairment unless the benefits clearly outweigh the risks.